# Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136

> **NCT00751348** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 475 (actual)

## Conditions studied

- Measles
- Varicella
- Mumps
- Rubella

## Interventions

- **BIOLOGICAL:** PriorixTM
- **BIOLOGICAL:** VarilrixTM
- **BIOLOGICAL:** Priorix-Tetra®

## Key facts

- **NCT ID:** NCT00751348
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-01
- **Primary completion:** 2010-05-27
- **Final completion:** 2010-05-27
- **Target enrollment:** 475 (ACTUAL)
- **Last updated:** 2018-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00751348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00751348, "Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00751348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*